Investor Relations & Strategy Officer with Science Background

Are you looking for a highly versatile role in a thriving growth company?

If you’re seeking a position that offers more variety than the average role, you’ve just found it. To excel in this position, however, you’ll need a solid foundation in the natural sciences to effectively address potential investors’ inquiries and strategic areas, which often involve scientific questions about our business and drug candidates.

You’ll have the opportunity to work closely with Gubra’s top management while handling diverse tasks across investor relations, strategy, and M&A. You’ll be entrusted with significant responsibilities, allowing you to personally influence the ongoing growth of a highly successful company listed on NASDAQ Copenhagen main market. 

Key responsibilities in Direct Collaboration with Top Management

Your primary role will be to support top management by managing a range of tasks across your three areas of focus. It is anticipated that you will dedicate approximately 50% of your time to investor relations (IR), 25% to strategy-related work, and 25% to M&A activities.

Investor Relations

• In the IR area, you will engage in dialogues with investors, develop presentation materials, and prepare external financial reports and company announcements, among other tasks. You will also conduct investor targeting and contribute to Gubra’s external positioning.

Strategy Work

• For strategy-related tasks, you will work both operationally and analytically. Your responsibilities will include organizing management and board meetings, preparing materials, taking minutes, and following up. Additionally, you will perform various analyses, such as competitor assessments and market trend evaluations.

M&A Activities

• As a biotech company, mergers and acquisitions (M&A) and partnerships are integral to our business model. You will collaborate with the Business Development team to manage M&A cases, licensing discussions, and related activities.

Your new workplace will be Gubra’s headquarters in Hørsholm, Denmark, where you will be part of the Finance team, reporting to our CFO.

Background in Management Consulting, Corporate Finance, or Biotech/Pharma

This central role, close to top management, requires drive, strong organizational skills, and the ability to prioritize multiple tasks effectively.

You should also thrive in an environment that retains some entrepreneurial characteristics. Everything is not predefined, and you will need a combination of creativity and the courage to explore new approaches. Moreover, you should be capable of presenting cases convincingly and energetically. 

Additionally, your qualifications include:

• A university degree in natural sciences (not mandatory but highly advantageous)
• Preferably experience as a management consultant, in corporate finance, or in a similar role within the biotech/pharma industry
• Excellent communication skills, including proficiency in writing and creating presentation materials (e.g., PowerPoint).

Contact and Application

Please apply through our website using the “Apply” button. The deadline is January 12, 2025. Candidates will be invited for interviews on a rolling basis, and we reserve the right to close the posting before the expiration date. If you have questions, feel free to contact CFO Kristian Borbos at +45 3080 8035.

We look forward to receiving your application.
 

About Gubra
Gubra is an ambitious contract research organisation (CRO) and biotech company striving for excellence at all levels. We insist on doing things efficiently – and often differently - to reach the results we aim for. Our vision is to become leaders in the fight for a more sustainable and healthier world. We do that by facilitating the discovery of new medicine, and by acting and inspiring others to fight the ongoing climate and biodiversity crises. Gubra’s activities are focused on the early stages of drug development and are organised in two highly synergistic business areas: CRO Services and Discovery & Partnerships (D&P). We generate our revenue by performing research for life science companies as well as by partnering projects from our discovery and development pipeline. Since 2023, Gubra is listed on NASDAQ Copenhagen.

Our therapeutic focus is within metabolic and fibrotic diseases, and we specialize in in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. In addition, we offer a full palette of advanced transcriptomics. Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit into a non-clinical candidate ready for development. Through a constant focus on high quality, scientific excellence, speed, and solid teamwork we have established ourselves as a highly professional and competent partner in the market.  

People are our greatest asset, and our team consists of +250 employees located in Hørsholm, Denmark and Boston in the US. The mix of people from different cultures and educational backgrounds combined with our entrepreneurial mindset have greatly impacted our working environment, which is characterized by entrepreneurial drive, scientific curiosity, and teamwork – we join forces!